The AMA Voted to Undo RFK Jr.’s Peptide Policy. Medspas Offering BPC-157 Are Building on a Policy That Can Disappear With One Memo.
By Kate Dee, MD — Founder, MedSpa Board
On November 9, the American Medical Association’s House of Delegates voted to urge HHS and the FDA to “immediately rescind” any policy that eases restrictions on compounding unapproved synthetic peptides. It also committed to pushing state medical and pharmacy boards for swift enforcement against compounding pharmacies, direct-to-consumer telehealth platforms and online sellers.
The AMA did not name the policy, but there is only one: the interim enforcement discretion policy Health Secretary Robert F. Kennedy Jr. signed on October 28. It tells pharmacies and physicians that HHS will not take action against them for compounding six unapproved peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.
The AMA has no legal power over Kennedy’s policy, but state boards listen to it
The AMA is a private professional association, not a regulator. Its vote cannot rescind a federal policy or discipline anyone. What it has is influence, as one of the most powerful lobbies in health care and with state boards whose members are mostly physicians.
Those boards are not bound by Kennedy’s policy. Earlier this year, medical boards from Alabama, Mississippi and South Carolina released statements that non-FDA-approved peptides may not be prescribed or compounded. The AMA is now asking every state to take a hard line.
The vote puts the country’s largest physician organization on record that any drug should be shown to be safe and effective before patients receive it. That should not be a controversial position.
Kennedy’s office overrode the FDA’s own scientists on peptide compounding
The policy came from the HHS Secretary’s office, not the FDA. According to the Associated Press, the FDA’s scientific staff had little input and opposed it.
The FDA restricted BPC-157 in 2023, citing possible immune reactions, impurities and very limited safety data. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend six peptides anyway. HHS had stacked the committee with eight new members before the vote, six of whom were in the business of selling peptide products. The FDA’s briefing materials found the available studies, including five on BPC-157, too small and too short to establish safety or effectiveness. Doctors and scientists across the country believe that that committee was violating logic and evidence when it took that vote.
Kennedy’s stated rationale is “patient choice and freedom.” Demand is not evidence. On this question the AMA sided with the FDA’s scientists.
The MedSpa Board does not take an anti-peptide stance. We stand for safety and legal compliance. Both must be present for any medical practice. Just because some things are safe does not mean they are legal. And just because some things are legal does not mean they are safe. A vial from a licensed compounding pharmacy is safer than a research-use-only vial from a website. But a clean vial of an unstudied drug is still an unstudied drug without any proof of safety.
HHS’s peptide policy is temporary, covers single peptides only, and can be withdrawn
Enforcement discretion is not legalization. The policy approves no peptide and binds no state. It lasts only until each peptide is addressed in a final rule, and HHS can revise or withdraw it before then, including if a safety signal appears.
The conditions are narrow. The ingredient must come from an FDA-registered manufacturer with a certificate of analysis. Each product needs a prescription for an identified patient and must be made by a 503A pharmacy, not a 503B outsourcing facility. Each product may contain only one peptide, so the popular BPC-157 and TB-500 “Wolverine” blend does not qualify. Anything sold “not for human use” is outside the policy entirely.
A medspa that builds a peptide prescribing business on this policy is depending on a decision one cabinet secretary can reverse. And anyone prescribing unapproved peptides is not operating within the standard of care and is risking their license. Multiple states and now the AMA have made that very clear.
Hims & Hers is signing up customers for BPC-157 and TB-500
The same week as the AMA vote, Hims & Hers put up a sign-up page for a new peptide program that is not yet available. The company says it will start with NAD+, sermorelin and glutathione, and will add BPC-157 and TB-500 if federal policy allows. Its own page says none of these products are FDA-approved.
Hims & Hers built a large compounded GLP-1 business, and clinics that charged premium prices for semaglutide know how that went. The AMA named direct-to-consumer telehealth platforms as enforcement targets. A medspa that builds its peptide business on this policy can lose it twice: once to Hims on price, and again when the policy ends.
MedSpa Board certification verifies who prescribes and where every drug comes from
The MedSpa Board has no certification rule specific to compounded peptides; federal and state law govern. Certification verifies the basics every peptide decision rests on: a medical director who provides active oversight, a physician, NP or PA who examines each patient before prescribing, and products from traceable, approved sources.
If you run a medspa and your standards are ready to be verified, begin your application now. If you want to see where you stand first, download our free checklist that tells you all the requirements to become certified.
— Kate Dee, MD
Sources & further reading
- American Medical Association, “AMA adopts new policies to protect patients and strengthen public health,” November 9, 2026. https://www.ama-assn.org/press-center/ama-press-releases/ama-adopts-new-policies-protect-patients-and-strengthen-public
- Becker’s Hospital Review, “New AMA policy targets unapproved peptide compounding,” November 10, 2026. https://www.beckershospitalreview.com/glp-1s/new-ama-policy-targets-unapproved-peptide-compounding/
- Medical Daily, “AMA Urges HHS to Rescind Policies Easing Compounding of Unapproved Peptides as BPC-157 Comment Window Nears Close,” November 2026. https://www.medicaldaily.com/ama-opposes-unapproved-peptide-compounding-policy-481192
- U.S. Department of Health and Human Services, “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,” Federal Register, filed October 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf
- Venable LLP, “HHS Announces Interim Enforcement Discretion for Section 503A Compounding with Certain Peptide Bulk Drug Substances,” November 2026. https://www.venable.com/insights/publications/2026/11/hhs-announces-interim-enforcement-discretion
- Healio, “HHS further loosens restrictions for several peptides,” October 29, 2026. https://www.healio.com/news/primary-care/20261029/hhs-further-loosens-restrictions-for-several-peptides
- Phil Taylor, pharmaphorum, “Hims & Hers to offer unapproved peptides to customers,” November 10, 2026. https://pharmaphorum.com/news/hims-hers-offer-unapproved-peptides-customers
- American Med Spa Association, “Hims & Hers Plans Launch of Peptide Treatments Following Federal Policy Shift,” November 10, 2026. https://www.americanmedspa.org/?p=21585
- Alabama Board of Medical Examiners, “Board Issues Official Notice Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides.” https://www.albme.gov/press-release/board-issues-official-notice-concerning-the-prescribing-of-non-fda-approved-research-grade-peptides

